Glucotrack Finalizes Resale of Warrants, Enabling 354% Dilution by Selling Stockholders

summarizeResume

This 424B3 filing finalizes the registration of shares underlying warrants issued in a December 2025 private placement, enabling selling stockholders to resell up to 3,224,803 shares. While the private placement provided crucial capital to the micro-cap company, which faces a "going concern" warning and a history of Nasdaq compliance issues, the subsequent resale of shares by investors will not generate any proceeds for Glucotrack. The potential for over 354% dilution of outstanding common stock creates a significant overhang on the share price and could lead to substantial downward pressure as these shares become available for sale in the market.

check_boxEvenements cles

• Finalizes Resale Offering

  Glucotrack, Inc. filed a final prospectus (424B3) to register 3,224,803 shares of common stock for resale by selling stockholders. This finalizes the offering initiated by the S-3 registration statement filed on January 13, 2026.

• Massive Potential Dilution

  The shares registered for resale represent approximately 354% of the company's currently outstanding common stock, indicating extreme potential dilution for existing shareholders.

• No Proceeds to Company

  Glucotrack will not receive any proceeds from the sale of these shares by the selling stockholders, as this is a secondary offering.

• Origin from Private Placement

  The shares originate from warrants issued in a private placement that closed on December 31, 2025, which provided approximately $4.0 million in gross proceeds to the company.

auto_awesomeAnalyse

This 424B3 filing finalizes the registration of shares underlying warrants issued in a December 2025 private placement, enabling selling stockholders to resell up to 3,224,803 shares. While the private placement provided crucial capital to the micro-cap company, which faces a "going concern" warning and a history of Nasdaq compliance issues, the subsequent resale of shares by investors will not generate any proceeds for Glucotrack. The potential for over 354% dilution of outstanding common stock creates a significant overhang on the share price and could lead to substantial downward pressure as these shares become available for sale in the market.